Advertisement

Topics

First-of-its-kind blood test unlocks precision treatment options for prostate cancer

04:35 EDT 19 Jun 2017 | Pharmafile

AstraZeneca’s (olparib) Lynparza is making yet another impact following its impressive showing this month in the ovarian cancer space, with the presentation of a new liquid biopsy test which could identify ideal candidates to be treated with the drug in men suffering from prostate cancer.

read more

Original Article: First-of-its-kind blood test unlocks precision treatment options for prostate cancer

NEXT ARTICLE

More From BioPortfolio on "First-of-its-kind blood test unlocks precision treatment options for prostate cancer"

Quick Search
Advertisement
 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...